XML 43 R21.htm IDEA: XBRL DOCUMENT v3.25.2
Income taxes
 12 Months Ended
May 25, 2025
Income Tax Disclosure [Abstract]  
Income taxes Income taxes
All of the Company’s income or loss from continuing operations before income tax is derived from its domestic operating subsidiaries. The following table presents the components of the provision for income taxes from continuing operations:
Year ended
May 25, 2025May 26, 2024
Current:
Federal$14 $(10)
State148 37 
Total162 27 
Deferred:
Federal(124)173 
State5 (17)
Total(119)156 
Income tax provision
$43 $183 
Income tax expense differs from the amount calculated using the 21% statutory U.S. federal income tax rate as follows:
Year ended
May 25, 2025May 26, 2024
Tax at U.S. statutory rate
$(8,122)$1,998 
State income taxes, net of federal benefit(197)52 
Compensation-related activity
799 418 
Return to provision adjustments
213 3,136 
Deferred tax write-offs
(748)711 
Tax credit carryforwards(539)(518)
Other96 158 
Change in valuation allowance8,541 (5,772)
Income tax expense
$43 $183 
The following table presents the components of deferred tax assets and liabilities reported in the balance sheets:
Year ended
May 25, 2025May 26, 2024
Deferred tax assets:
Net operating loss carryforwards$40,677 $40,806 
Limitations on business interest expense15,573 11,783 
Research credit carryforwards7,116 6,700 
Capitalized research and development
3,767 2,916 
Other6,338 4,609 
Deferred tax assets before valuation allowance
73,471 66,814 
Less: valuation allowance
(54,714)(46,173)
Deferred tax assets
18,757 20,641 
Deferred tax liabilities:
Depreciation
(10,735)(11,809)
Debt derivative liability and related debt discount
(7,026)(7,911)
Other
(1,419)(1,464)
Deferred tax liabilities(19,180)(21,184)
Net deferred tax liability
$(423)$(543)
The Company continues to maintain a full valuation allowance against its U.S. and state deferred tax assets based on available positive and negative evidence, including historical losses during the most recent three-year period. The Company will re-evaluate the need for a valuation allowance in future periods based on its operating results as a standalone entity.
The following table presents the amounts and expiration dates of net operating loss and tax credit carryforwards as of May 25, 2025:
Net operating loss carryforwards
Research and development credits
Amount
Begin to expire
Amount
Life
Begin to expire
Federal$172,048 2028$3,858 20 years2033
California
52,239 20252,058 unlimitednone
All other states
16,512 20252,024 15 years2029
The Federal net operating loss carryforwards presented in the table above include $164,770 with no expiration date. The Company estimated utilization of $2,051 and $3,907 of Federal net operating loss carryforwards and no material state operating loss carryforwards for the fiscal years ended May 25, 2025 and May 26, 2024, respectively.
As of May 25, 2025, the total amount of net unrecognized tax benefits is $1,323, of which $1,186, if recognized, would affect the effective tax rate. No interest and penalties have been accrued as of May 25, 2025. The Company has not had, and does not expect to have, any significant increase or decrease to its unrecognized tax benefits within the next twelve months.
Due to tax attribute carryforwards, the Company is subject to examination for tax years 2012 forward for U.S. tax purposes. The Company was also subject to examination in various state jurisdictions for tax years 2012 forward.
New tax legislation was passed subsequent to year-end, see note 18 for additional information.